It interacts with MMPs and matrix serine proteases like plasminogen activator to limit tumour growth and angiogenesis in a variety of malignancies, and it is recognized as a key ECM‐modifying enzyme.51,52 THBS2 has been identified as a potential biomarker with clinical prognosis in CRC,44, 45 and the patients with positive THBS2 expression had a significantly lower likelihood of liver metastasis,46 and up‐regulated was linked to poor overall survival.47 Here, THBS2 is linked to colorectal carcinoma.